Maruho Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Maruho Co., Ltd.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.
The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen.
Upstream Bio acquired Phase Ib-ready UPB-101 from Astellas, and its experienced team plans to buy additional drug candidates for the treatment of allergic and inflammatory diseases.
- Specialty Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.